Applications are invited for post of Chief Executive Officer at RCB | Emoluments upto Rs. 1.50 lakh pm
Regional Centre for Biotechnology (RCB) is an institution for education, training and research established by the Govt. of India under the auspices of UNESCO in a wide range of biotechrelated sciences. RCB is situated in the NCR Biotech Science Cluster (NBSC) developed by the Department of Biotechnology, Government of India, on a 200-acre site located at the Faridabad- Gurgaon expressway within the NCR Delhi, along with other constituent institutions. RCB is in the process of establishing an Office of Connectivity (OoC) to manage and nurture the development of the NCR Biotech Science Cluster. We are looking for dynamic, result-oriented and dedicated candidates for the following contractual positions for the OoC on direct recruitment (DR) / deputation basis. The project duration is initially till March 2019 but is likely to be extended further.
Post : Chief Executive Officer (CEO)

Clinical Development Services Agency (CDSA) has therefore been formed as a not-for-profit society to provide supportive and focused environment to host world class clinical translation through a collaborative network of clinical investigators and premier research institutions. It will tend enterprises, particularly SMEs involved in new technology innovation, to facilitate translation of scientific know-how into viable products for public health diseases like malaria, tuberculosis and dengue among others.
Boehringer Ingelheim is a research-driven pharmaceutical company and one of the top 20 pharmaceutical firms worldwide. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally in over 100 countries and has more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 23.1% of its net sales.


